KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Other financing activities (2020 - 2023)

GoodRx Holdings' Other financing activities history spans 4 years, with the latest figure at $3.7 million for Q1 2023.

  • For Q1 2023, Other financing activities fell 61.2% year-over-year to $3.7 million; the TTM value through Dec 2025 reached -$13.8 million, down 30.9%, while the annual FY2024 figure was $2.7 million, N/A changed from the prior year.
  • Other financing activities for Q1 2023 was $3.7 million at GoodRx Holdings, up from -$17.6 million in the prior quarter.
  • Across five years, Other financing activities topped out at $81.7 million in Q4 2020 and bottomed at -$42.9 million in Q4 2021.
  • The 4-year median for Other financing activities is $4.7 million (2022), against an average of $7.8 million.
  • The largest YoY upside for Other financing activities was 3019.29% in 2021 against a maximum downside of 152.54% in 2021.
  • A 4-year view of Other financing activities shows it stood at $81.7 million in 2020, then plummeted by 152.54% to -$42.9 million in 2021, then soared by 59.11% to -$17.6 million in 2022, then surged by 121.13% to $3.7 million in 2023.
  • Per Business Quant, the three most recent readings for GDRX's Other financing activities are $3.7 million (Q1 2023), -$17.6 million (Q4 2022), and $3.3 million (Q3 2022).